Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -304.28% |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.28% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -15.70% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 13.47% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 30.20% |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 385.28% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | -99.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.20% |
| Mar 31, 2026 | 2,383.26% |
| Dec 31, 2025 | 50.82% |
| Sep 30, 2025 | 64.24% |
| Jun 30, 2025 | 70.13% |
| Mar 31, 2025 | -81.60% |
| Dec 31, 2024 | -32.01% |
| Sep 30, 2024 | 51.41% |
| Jun 30, 2024 | -34.36% |
| Mar 31, 2024 | 153.10% |
| Dec 31, 2023 | 62.50% |
| Sep 30, 2023 | 18.79% |
| Jun 30, 2023 | 639.15% |
| Mar 31, 2023 | -653.92% |
| Dec 31, 2022 | 1,306.85% |
| Sep 30, 2022 | 200.45% |
| Jun 30, 2022 | -140.83% |
| Mar 31, 2022 | -56.43% |
| Dec 31, 2021 | -102.10% |
| Sep 30, 2021 | 137.30% |